Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

1. Peters, S.
2. Dafni, U.
3. Boyer, M.
4. De Ruysscher, D.
5. Faivre-Finn, C.
6. Felip, E.
7. Garrido, P.
8. Girard, N.
9. Guckenberger, M.
10. Haanen, J.
11. Le Pechoux, C.
12. Mornex, F.
13. Ozsahin, M.
14. Paz-Ares, L.
15. Planchard, D.
16. Raben, D.
17. Ramalingam, S.
18. Reck, M.
19. Smit, E.
20. Stahel, R.
21. Stenzinger, A.
22. Swanton, C.
23. Vallone, S.
24. Garassino, M.C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDY553 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus